Post-inflammatory administration of
N‐acetylcysteine (NAC)
Parkinson's disease
alpha‐synuclein (α‐syn)
apoptosis
neuroinflammation
Journal
FASEB bioAdvances
ISSN: 2573-9832
Titre abrégé: FASEB Bioadv
Pays: United States
ID NLM: 101733210
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
30
12
2022
revised:
10
04
2023
accepted:
28
04
2023
medline:
7
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Parkinson's disease (PD) is a complex, multifactorial neurodegenerative disease with a prevalence of 1% over the age of 55. Neuropathological hallmarks of PD include the loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies that contain a variety of proteins and lipids including alpha-synuclein (α-syn). Although the formation of α-syn occurs intracellularly, it can also be found in the extracellular space where it can be taken up by neighboring cells. Toll-like receptor 2 (TLR2) is an immune system receptor that has been shown to recognize extracellular α-syn and modulate its uptake by other cells. Lymphocyte-activation gene 3 (LAG3), an immune checkpoint receptor, has also been proposed to play a role in extracellular α-syn internalization; however, a recent study has disputed this role. Internalized α-syn can trigger expression and secretion of inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-2, and IL-6 and induce neuroinflammation, apoptosis, and mitophagy that results in cellular death. In this study, we tested if
Identifiants
pubmed: 37415931
doi: 10.1096/fba.2022-00145
pii: FBA21377
pmc: PMC10320847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
263-276Informations de copyright
©2023 The Authors FASEB BioAdvances published by The Federation of American Societies for Experimental Biology.
Déclaration de conflit d'intérêts
The authors declare they have no conflicts of interest.
Références
CMAJ. 2016 Nov 1;188(16):1157-1165
pubmed: 27221269
Parkinsonism Relat Disord. 2015 May;21(5):500-3
pubmed: 25765302
Mol Neurobiol. 2019 Jul;56(7):4799-4811
pubmed: 30397850
Mol Neurobiol. 2013 Apr;47(2):495-508
pubmed: 22622968
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
J Neurol Sci. 2017 Oct 15;381:308-314
pubmed: 28991704
Neurosci Res. 2011 Apr;69(4):337-42
pubmed: 21255620
J Neuroinflammation. 2008 Oct 17;5:45
pubmed: 18925972
Neurosci Biobehav Rev. 2015 Aug;55:294-321
pubmed: 25957927
Sci Rep. 2018 Oct 2;8(1):14600
pubmed: 30279468
Mol Neurodegener. 2012 Aug 24;7:42
pubmed: 22920859
PLoS One. 2013;8(1):e55375
pubmed: 23383169
Biomolecules. 2018 Aug 01;8(3):
pubmed: 30071596
Int Rev Cell Mol Biol. 2008;270:225-317
pubmed: 19081538
Trends Pharmacol Sci. 2013 Mar;34(3):167-77
pubmed: 23369637
Cell Signal. 2010 Jul;22(7):977-83
pubmed: 20096353
FEBS J. 2012 Apr;279(7):1146-55
pubmed: 22314200
Acta Neuropathol. 2017 Feb;133(2):303-319
pubmed: 27888296
J Neuroimmunol. 1990 Dec;30(2-3):213-7
pubmed: 2229409
Mediators Inflamm. 2014;2014:861231
pubmed: 24966471
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Neurosci Lett. 1994 Jan 3;165(1-2):208-10
pubmed: 8015728
Neurobiol Dis. 2015 Feb;74:180-93
pubmed: 25478815
Curr Opin Pharmacol. 2007 Aug;7(4):355-9
pubmed: 17602868
N Engl J Med. 2013 Feb 14;368(7):610-22
pubmed: 23406026
Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S48-52
pubmed: 11840215
Antioxid Redox Signal. 2013 Aug 20;19(6):546-58
pubmed: 22978471
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
Structure. 2011 Apr 13;19(4):447-59
pubmed: 21481769
Neurosci Lett. 2000 Jun 30;287(3):211-4
pubmed: 10863032
Free Radic Biol Med. 2013 Sep;62:13-25
pubmed: 23665395
J Neurophysiol. 2010 Nov;104(5):2523-31
pubmed: 20810691
EMBO Mol Med. 2021 Sep 7;13(9):e14745
pubmed: 34309222
Molecules. 2018 Dec 13;23(12):
pubmed: 30551603
FEBS Lett. 2015 Dec 21;589(24 Pt A):3749-59
pubmed: 26505673
Lancet Neurol. 2010 Jun;9(6):581-91
pubmed: 20434403
Oxid Med Cell Longev. 2018 Dec 30;2018:3987941
pubmed: 30693062
Biology (Basel). 2020 Apr 23;9(4):
pubmed: 32340360
Stroke. 1994 Jul;25(7):1481-8
pubmed: 8023366
Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1056-64
pubmed: 18286589
Expert Opin Ther Targets. 2015 May;19(5):589-603
pubmed: 25785645
EMBO J. 2007 Jan 24;26(2):494-504
pubmed: 17245433
Transl Neurodegener. 2015 Oct 12;4:19
pubmed: 26464797
N Engl J Med. 1991 Aug 15;325(7):467-72
pubmed: 1852181
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
Curr Pharm Des. 2008;14(32):3408-16
pubmed: 19075717
CNS Neurol Disord Drug Targets. 2011 May;10(3):391-403
pubmed: 21288189
J Autoimmun. 2020 Aug;112:102504
pubmed: 32576412
Brain Behav Immun. 2019 Oct;81:41-51
pubmed: 31271873
Neuron. 2008 Jun 12;58(5):673-80
pubmed: 18549780
Nat Rev Neurol. 2013 Jan;9(1):13-24
pubmed: 23183883
J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117
pubmed: 23054368
Front Pharmacol. 2018 May 04;9:417
pubmed: 29780321
J Neuroinflammation. 2019 Dec 17;16(1):270
pubmed: 31847878
Biochim Biophys Acta. 2015 Mar;1852(3):451-61
pubmed: 25481834
FEBS J. 2021 Dec;288(23):6593-6602
pubmed: 33332736
Int Immunol. 2005 Jan;17(1):1-14
pubmed: 15585605
Biochim Biophys Acta. 2015 Dec;1850(12):2497-505
pubmed: 26391842
J Neurol Sci. 2012 Feb 15;313(1-2):57-63
pubmed: 22001247
J Int Neuropsychol Soc. 2016 Nov;22(10):956-967
pubmed: 27903331
Acta Neurol Belg. 2017 Mar;117(1):43-51
pubmed: 27473175
Neurosci Lett. 1994 May 19;172(1-2):151-4
pubmed: 8084523
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Neuroscience. 2001;104(3):901-12
pubmed: 11440819
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Neurosci Lett. 1991 Aug 19;129(2):318-20
pubmed: 1745413
Mov Disord. 2007 Jul 30;22(10):1379-1389
pubmed: 17427940
Molecules. 2019 Jan 15;24(2):
pubmed: 30650656
Neuron. 2016 May 18;90(4):675-91
pubmed: 27196972
Int J Neuropsychopharmacol. 2014 Dec 07;18(6):
pubmed: 25522431
Semin Immunol. 2007 Feb;19(1):24-32
pubmed: 17275323